ViCentra Elevates Leadership with Reman McDonagh's Appointment
ViCentra, a notable player in the medical device field known for the Kaleido insulin patch pump system, has recently announced a significant addition to its executive team. Reman McDonagh, PhD, a seasoned professional with over two decades of experience in the diabetes sector, has been appointed as Vice President of Global Marketing. This strategic decision is aimed at reinforcing the company’s leadership as it ramps up operations in Europe while preparing to launch the innovative Kaleido system.
With an impressive background in diabetes and medical device commercialization, McDonagh brings with her a wealth of knowledge and expertise. Her career encompasses pivotal roles in prestigious organizations such as Roche, Medtronic, Cellnovo, and Insulet. At these companies, she was instrumental in developing brand strategies, market planning, and executing significant product launches across various markets.
Her onboarding comes at a critical moment for ViCentra, which is experiencing robust growth momentum supported by a recent $98 million Series D financing round. This funding is set to fortify the groundwork for upcoming expansion efforts and support the company’s vision for the next-generation Kaleido system.
In remarks regarding her new role, Tom Arnold, Chief Executive Officer of ViCentra, expressed optimism. He stated, "Reman joins ViCentra at a pivotal stage as we transition from strong early traction to disciplined, scalable growth. She brings a rare combination of deep diabetes expertise, end-to-end marketing leadership, and operational rigor, as we strengthen our presence in key European markets and prepare for U.S. market entry."
Prior to joining ViCentra, McDonagh undertook a series of significant international marketing roles with Insulet, where she was responsible for the direct launch of Omnipod DASH in twelve European countries and played a key role in formulating Insulet's European launch strategy for Omnipod 5.
In her new capacity at ViCentra, McDonagh will spearhead the global marketing strategy. This includes enhancing the value proposition of the Kaleido system, stimulating demand in priority European markets, and ensuring readiness across multiple functions for the impending product launches.
McDonagh shared her enthusiasm for joining the team, stating, "Kaleido is a truly differentiated insulin delivery system, and ViCentra has built meaningful momentum through a clear focus on the user experience. I'm excited to join the team as we scale in key markets and prepare for the next generation of Kaleido, bringing greater choice, flexibility, and freedom to more people living with diabetes."
Her academic credentials include a PhD in Chemistry. McDonagh has spearheaded international teams across marketing and commercial strategy, successfully supporting business units generating over $400 million in annual revenue.
Her appointment follows a series of strategic hires in senior commercial leadership at ViCentra, underscoring the company’s pledge to assemble a world-class team capable of executing a comprehensive growth strategy while making a significant impact on the lives of individuals living with diabetes.
About ViCentra
ViCentra is dedicated to enhancing the lives of diabetes patients through innovative solutions that emphasize empathy and design excellence. The firm proudly develops the Kaleido insulin patch pump system, an elegantly designed alternative to traditional insulin delivery methods. The company's headquarters is located in Utrecht, the Netherlands, and it is making strong strides to expand its operations throughout Europe while gearing up for market entry in the U.S. The company has garnered investment from a range of sources including Innovation Industries, Partners in Equity, Invest-NL, EQT Life Sciences, ROM Utrecht Region, Venturing Tech, Health Innovations, and INKEF.
About Kaleido
Kaleido is setting a new standard in wearable insulin delivery by being the first insulin patch pump crafted with the elegance of a lifestyle product. This device is compact, featherlight, and discreet, focusing on personal technology rather than merely a medical device. It is constructed from premium materials and offers customizable aluminum shells in a spectrum of colors, promoting self-expression alongside effective glycemic control. Users are empowered to choose how and where to wear their pumps, integrating diabetes management seamlessly into their lives.
As the smallest and lightest insulin patch pump in its category, Kaleido delivers advanced automated insulin therapy through a seamless integration with Diabeloop's clinically validated hybrid closed loop algorithms, DBLG1 and DBLG2.
Frequently Asked Questions
Who is Reman McDonagh?
Reman McDonagh is the newly appointed Vice President of Global Marketing at ViCentra, bringing over 20 years of experience in the diabetes field.
What is Kaleido?
Kaleido is an innovative insulin patch pump system designed by ViCentra, offering a compact and discreet alternative for insulin delivery.
What is ViCentra's mission?
ViCentra's mission revolves around improving the lives of individuals with diabetes through innovative products that merge ease of use and design excellence.
What recent funding has ViCentra received?
ViCentra recently completed a $98 million Series D financing round to support its growth and the upcoming launch of the Kaleido system.
Where is ViCentra headquartered?
ViCentra is headquartered in Utrecht, the Netherlands, with plans for expansion across Europe and future entry into the U.S. market.
